Sanofi aims to sell Allegra plant ahead of 2016 shutdown

By Gareth Macdonald contact

- Last updated on GMT

Sanofi to sell Kansas Allegra plant
Sanofi to sell Kansas Allegra plant
Sanofi has confirmed it wants to sell the Kansas City facility at which it makes the allergy drug Allegra (Fexofenadine).

Unconfirmed reports this week suggested the French drugmaker Sanofi had decided to sell the Kansas City plant and hired a commercial real estate agent to help it find a buyer.

A Sanofi spokeswoman confirmed the report, telling in-Pharmatechnologist.com that plan is to sell “both the equipment and the site itself.​”

She also confirmed that the facility produces the allergy treatment Allegra (Fexofenadine) and a number of other pharmaceutical products.

The site has been earmarked for closure since 2009​ when Sanofi said that falling demand for the drug made continued operation of the facility economically unviable.

Since then Sanofi has been gradually laying of the 390 staff employees at the site and reducing manufacturing levels.

According to an official statement emailed to this publication “all manufacturing will cease by August 2016, and we intend to sell both the building and manufacturing equipment​.”

Related news

Related products

show more

Why Blister Packaging: Things to Consider

Why Blister Packaging: Things to Consider

Catalent Pharma Solutions | 03-Dec-2020 | Insight Guide

The decision to use blister packaging for either clinical trials or commercial drug manufacturing comes with a host of factors to consider. Pharmaceutical...

Strategies to Achieve Successful Approval & Launch

Strategies to Achieve Successful Approval & Launch

Catalent Pharma Solutions | 03-Sep-2020 | Data Sheet

There are several key considerations to how companies should approach commercial-scale manufacturing that may aid the success of their biologic’s launch...

Related suppliers

Follow us

Products

View more

Webinars